TII
5.7.2022 11:16:08 CEST | Business Wire | Press release
The Technology Innovation Institute (TII), a leading global research center and the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC) today announced that its Directed Energy Research Center (DERC), will organize the upcoming edition of GLOBALEM, a definitive high power electromagnetic (HPEM) conference.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220705005033/en/
Set to run from November 13 to 17 at St. Regis Abu Dhabi, the conference marks the first high-profile event DERC is hosting after the launch of its prequalification testing facility at Tawazun Industrial Park in Abu Dhabi dedicated to a specific high-energy physics domain.
Dr. Chaouki Kasmi, Chief Researcher, Directed Energy Research Center, will offer expertise as General Chair of the organizing committee of GLOBALEM. Other expert members include Dr. Bill Radasky, of Metatech Corporation USA, and Dr. Nicolas Mora from DERC as joint Technical Program Committee co-chairs, as well as Dr. Felix Vega from DERC, Dr. Lars Ole Fichte from the Helmut-Schmidt University in Hamburg, Germany, and Dr. Jane Lehr, from the University of New Mexico, USA, as conference advisors.
Unpacking the challenges and opportunities that currently exist as well as those evolving everyday in the crucial field of electromagnetics, the conference is set to draw the interest of experts from fields as diverse as pulsed power technologies, high voltage generator, microwaveradiation, covering analytical and numerical modeling as well as experimental validation
All eyes will be trained on the Best Student Paper Award (BSPA), with award recipients receiving a certificate and a cash prize of US$500.
Likewise, the Young Scientist Award (YSA) recognizes a young researcher under 35 who has made innovative contributions in fields related to HPEM. Researchers keen to participate in the contest can nominate themselves during the submission process.
For both awards, the last date for the submission of extended abstracts online is July 1, 2022. Acceptance confirmations and nominations will be completed by August 15, and September 15 is the last date for the final review and submission of full papers and award nominations. Early bird registration is open until September 30, 2022.
Highlighting the significance of the conference for the TII ecosystem and for Abu Dhabi as well, Dr. Kasmi said: “The GLOBALEM conference promises to be a game changer for the region. High Power Electromagnetics is one of those hot areas in focus today for us at DERC, given the varied number of applications and sectors it straddles – from your everyday generators, motors, and transformers, to maglev trains, and astronomy to health care and everything in between. We are even focusing on new innovations that can treat certain types of cancer. Being able to convene so many global experts in Abu Dhabi is unprecedented and is a big deal for TII and the region.”
For more information on the GLOBALEM Conference 2022, and to submit scientific papers please visit: https://globalem2022.com/submission.php
About the Technology Innovation Institute (TII)
The Technology Innovation Institute (TII) is the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), and a leading global scientific research center that focuses on shaping breakthrough solutions and new-age technology capabilities. In working with exceptional talent, universities, research institutions and industry partners from around the world, TII connects an intellectual community and contributes to building a thriving R&D ecosystem that elevates the status of Abu Dhabi and the UAE as a global hub for innovation. For more information, please visit www.tii.ae
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005033/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom